skip to Main Content
What is the Clozapine REMS?

The Clozapine Risk Evaluation and Mitigation Strategy (REMS) is a crucial safety program mandated by the U.S. Food and Drug Administration (FDA). Its primary goal is to monitor and mitigate the risk of severe neutropenia—a condition characterized by a dangerously low level of neutrophils (a type of white blood cell)—that can occur with clozapine treatment. Severe neutropenia, defined as an absolute neutrophil count (ANC) less than 500/µL, poses a significant threat as it can lead to severe and potentially fatal infections.

Patient Information

To ensure safe administration, patients must be enrolled in the Clozapine REMS program by a certified healthcare provider. This certification ensures that the provider has received the necessary training and understands the protocols required to manage and monitor the risks associated with clozapine treatment.

Clozapine REMS Certified MHP Providers
Amanda Jayaraman PMHNP
Amanda Jayaraman
PMHNP
Amy Card PMHNP
Amy Card
PMHNP
Pinkie Fitts
Pinkie Fitts
PMHNP
Olaf Garcia
PMHNP BC, AG-CNS

Find the Right Treatment for You

Back To Top